Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › APLLTD

APLLTD

Alembic Pharmaceuticals Limited
Small-capPharma ↗

What the six lenses say about APLLTD — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹799.5
2026-09-08
VWAP · 1Y anchor
₹831
-3.8% from VWAP
P/E · TTM
23.3×
TTM EPS ₹34.3
52-week range
46%
position low→high
RSI(14)
43
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How APLLTD’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
3.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD448›

The actual numbers

Price vs VWAP (1y)-3.8%
EMA trend stackMixed
Price vs 200-EMA-1.5%
Price vs 50-EMA-1.4%
RSI(14)43
RS vs Nifty 500 · 3M+2.8%
RS vs sector · 3M-3.2%
52-week range46%
Volume vs 30d avg1.55×
Volume vs 60d avg1.47×
ATR(14) · volatility27.1
Bollinger width · vol contraction0.060
FundamentalD547›

The actual numbers

Return on equity (ROE)11.8%
Operating margin10.7%
Net margin9.1%
Revenue growth · YoY+10.1%
EPS growth · YoY+15.8%
Debt / equity0.25×

Full 8-quarter history in the financials table below.

ValuationD953›

The actual numbers

P/E (TTM)23.3×
TTM EPS₹34.3
52-week range46%
CatalystD1073›

The actual numbers

Earnings & momentum114
Capital actions10
Governance102

Every filing in the corporate-announcements panel below.

FlowD342›

The actual numbers

Promoter holding69.7%
Delivery · 30d avg52.2%
Up/down-day asymmetry-5.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D4 + D3 ) ÷ 2 = 3.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Medium
47
Conviction score 47/100 · avg-decile strength 3.5/10
Conviction score47/100›
TechnicalD4›
FundamentalD5›
ValuationD9›
CatalystD10›
FlowD3›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.6pp
-3.0pp
-0.7pp
+4.4pp
+15.6pp
-11.6pp
Nifty 500
Broad-market baseline
-0.6pp
-3.0pp
-1.8pp
+2.8pp
+9.8pp
-16.8pp
Sector
Own-sector index
—
—
-4.6pp
-3.2pp
-3.3pp
-37.6pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

APLLTD daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
799.55-8.65

Relative strength

RS vs baseline · rebased to 100

APLLTD ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
67.44-0.44

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,5621,6481,6931,7701,7111,9101,8761,848
↳ change QoQ—+5.5%+2.7%+4.6%-3.3%+11.6%-1.8%-1.5%
EBITDA (₹cr)239269270271281316292228
EBITDA margin15.3%16.3%15.9%15.3%16.4%16.5%15.6%12.3%
PAT (₹cr)135153138157154184132202
↳ change QoQ—+13.8%-10.1%+14.0%-1.9%+19.5%-28.3%+53.0%
Net margin8.6%9.3%8.1%8.9%9.0%9.6%7.0%10.9%
EPS (₹)6.857.797.017.987.859.406.7610.31
D/E0.000.000.00—————
YoY growth · Mar '26Revenue +4.4% YoYPAT +28.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 7 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Aug '26
    LOWgovernance
    Change in Company Secretary/Compliance Officer
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    MEDIUMgovernance
    Resignation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    MEDIUMcapital
    Press Release (Revised)
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 28 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds APLLTD

Mutual funds holding APLLTD (10)

FundWeightAUM ₹crGrade
DSP Small Cap Reg Gr0.59%20,221
Kotak Small Cap Reg Gr1.44%18,933
DSP ELSS Tax Saver Reg Gr0.68%16,738
DSP Agrsv Hybrid Fund Reg Gr0.54%11,909
DSP Large cap Reg Gr0.58%7,228
ICICI Pru Pharma Healthcare Diag Gr2.43%6,803
DSP Healthcare Fund Reg Gr3.16%3,639
Abakkus Small Cap Reg Gr1.38%2,113
UTI Healthcare Reg Gr1.16%1,371
The Wealth Com Mlt Ast Allc Reg Gr1.12%193

ETFs holding APLLTD (0)

No tracked ETF holds APLLTD ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma